FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046081490> ?p ?o ?g. }

• W2046081490 endingPage "1931" @default.
• W2046081490 startingPage "1923" @default.
• W2046081490 abstract "Introduction To date, no approved medication is available for the treatment of female sexual arousal disorder (FSAD). Aim The purpose of this study was to evaluate the clinical efficacy and safety of a novel alprostadil topical cream for the treatment of FSAD. Methods This was a multicenter, randomized, double blind, placebo‐controlled, parallel design dose‐ranging study. Four hundred female patients with FSAD (22–62 years of age), after a 4‐week nontreatment baseline period, were provided with 10 blinded doses of 500, 700, or 900 mcg alprostadil or a placebo cream to be applied to the clitoris and the G‐spot in the vagina prior to vaginal intercourse. Main Outcome Measures The primary efficacy end point was the arousal success rate (equal number of the Yes responses to Question 3 of the Female Sexual Encounter Profile [FSEP] or number of the sexual encounters). Secondary endpoints included the Female Sexual Function Index (FSFI), Global Assessment Questionnaire, other FSEP question responses, and post‐treatment changes in Female Sexual Distress Scale. Results A total of 374 FSAD patients completed the study. Primary efficacy analysis of the intent‐to‐treat (ITT) population showed a significant increase in arousal success rates with dose. Arousal success rates at the end of the total evaluation period were 33.1%, 46.3% (P = 0.0161), 43.5% (P = 0.0400), and 53.9% (P = 0.0002) in the placebo, 500, 700, and 900 mcg alprostadil groups, respectively. The changes of the FSFI score, relative to baseline were 14.7%, 20.7% (P = 0.067), 21.7% (P = 0.035), and 22.9% (P = 0.002) for the placebo, 500, 700, and 900 mcg treatment groups, respectively. The other secondary efficacy end point values showed a consistent trend in support of the primary efficacy results. Conclusion These results demonstrated that the application of topical alprostadil prior to vaginal intercourse significantly improved the sexual arousal rate of the subjects with FSAD. Liao Q, Zhang M, Geng Li, Wang X, Song X, Xia P, Lu T, Lu M, and Liu V. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: A double‐blind, placebo‐controlled study in Chinese population. J Sex Med 2008;5:1923–1931." @default.
• W2046081490 created "2016-06-24" @default.
• W2046081490 creator A5008609148 @default.
• W2046081490 creator A5018021055 @default.
• W2046081490 creator A5023712848 @default.
• W2046081490 creator A5031663161 @default.
• W2046081490 creator A5036031567 @default.
• W2046081490 creator A5043300709 @default.
• W2046081490 creator A5046506979 @default.
• W2046081490 creator A5079980169 @default.
• W2046081490 creator A5080031897 @default.
• W2046081490 date "2008-08-01" @default.
• W2046081490 modified "2023-09-29" @default.
• W2046081490 title "Efficacy and Safety of Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder: A Double‐Blind, Placebo‐Controlled Study in Chinese Population" @default.
• W2046081490 cites W1967637710 @default.
• W2046081490 cites W1974338938 @default.
• W2046081490 cites W1989755880 @default.
• W2046081490 cites W1992676134 @default.
• W2046081490 cites W2006239717 @default.
• W2046081490 cites W2015192817 @default.
• W2046081490 cites W2031372686 @default.
• W2046081490 cites W2033842599 @default.
• W2046081490 cites W2034572972 @default.
• W2046081490 cites W2053764026 @default.
• W2046081490 cites W2058690971 @default.
• W2046081490 cites W2058748137 @default.
• W2046081490 cites W2067453382 @default.
• W2046081490 cites W2067814588 @default.
• W2046081490 cites W2069897728 @default.
• W2046081490 cites W2074693545 @default.
• W2046081490 cites W2090284371 @default.
• W2046081490 cites W2112997260 @default.
• W2046081490 cites W2120385927 @default.
• W2046081490 cites W2125021072 @default.
• W2046081490 cites W2126157729 @default.
• W2046081490 cites W2136485433 @default.
• W2046081490 cites W2147117726 @default.
• W2046081490 cites W2160698316 @default.
• W2046081490 cites W2161609948 @default.
• W2046081490 cites W2163721198 @default.
• W2046081490 cites W2415431864 @default.
• W2046081490 cites W3023728595 @default.
• W2046081490 cites W2040309594 @default.
• W2046081490 doi "https://doi.org/10.1111/j.1743-6109.2008.00876.x" @default.
• W2046081490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18564348" @default.
• W2046081490 hasPublicationYear "2008" @default.
• W2046081490 type Work @default.
• W2046081490 sameAs 2046081490 @default.
• W2046081490 citedByCount "30" @default.
• W2046081490 countsByYear W20460814902012 @default.
• W2046081490 countsByYear W20460814902013 @default.
• W2046081490 countsByYear W20460814902014 @default.
• W2046081490 countsByYear W20460814902015 @default.
• W2046081490 countsByYear W20460814902016 @default.
• W2046081490 countsByYear W20460814902017 @default.
• W2046081490 countsByYear W20460814902018 @default.
• W2046081490 countsByYear W20460814902019 @default.
• W2046081490 countsByYear W20460814902021 @default.
• W2046081490 crossrefType "journal-article" @default.
• W2046081490 hasAuthorship W2046081490A5008609148 @default.
• W2046081490 hasAuthorship W2046081490A5018021055 @default.
• W2046081490 hasAuthorship W2046081490A5023712848 @default.
• W2046081490 hasAuthorship W2046081490A5031663161 @default.
• W2046081490 hasAuthorship W2046081490A5036031567 @default.
• W2046081490 hasAuthorship W2046081490A5043300709 @default.
• W2046081490 hasAuthorship W2046081490A5046506979 @default.
• W2046081490 hasAuthorship W2046081490A5079980169 @default.
• W2046081490 hasAuthorship W2046081490A5080031897 @default.
• W2046081490 hasConcept C126322002 @default.
• W2046081490 hasConcept C139265228 @default.
• W2046081490 hasConcept C141071460 @default.
• W2046081490 hasConcept C142724271 @default.
• W2046081490 hasConcept C15744967 @default.
• W2046081490 hasConcept C168563851 @default.
• W2046081490 hasConcept C169760540 @default.
• W2046081490 hasConcept C202061045 @default.
• W2046081490 hasConcept C203092338 @default.
• W2046081490 hasConcept C204787440 @default.
• W2046081490 hasConcept C27081682 @default.
• W2046081490 hasConcept C2777744392 @default.
• W2046081490 hasConcept C2778577535 @default.
• W2046081490 hasConcept C2908647359 @default.
• W2046081490 hasConcept C29456083 @default.
• W2046081490 hasConcept C2991744798 @default.
• W2046081490 hasConcept C2993290233 @default.
• W2046081490 hasConcept C36951298 @default.
• W2046081490 hasConcept C70410870 @default.
• W2046081490 hasConcept C71924100 @default.
• W2046081490 hasConcept C99454951 @default.
• W2046081490 hasConceptScore W2046081490C126322002 @default.
• W2046081490 hasConceptScore W2046081490C139265228 @default.
• W2046081490 hasConceptScore W2046081490C141071460 @default.
• W2046081490 hasConceptScore W2046081490C142724271 @default.
• W2046081490 hasConceptScore W2046081490C15744967 @default.
• W2046081490 hasConceptScore W2046081490C168563851 @default.
• W2046081490 hasConceptScore W2046081490C169760540 @default.
• W2046081490 hasConceptScore W2046081490C202061045 @default.
• W2046081490 hasConceptScore W2046081490C203092338 @default.

• next